Literature DB >> 19080758

Inclusion body myositis: review of recent literature.

Steven A Greenberg1.   

Abstract

Inclusion body myositis (IBM) is a progressive inflammatory skeletal muscle disease of unknown cause and without effective treatment. This article discusses existing literature, emphasizing disease mechanisms and models. In particular, it addresses limitations in the beta-amyloid-mediated theory of IBM myofiber injury, flawed rationales of animal models of this disease, and recent reports regarding treatment.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19080758     DOI： 10.1007/s11910-009-0013-x

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  66 in total

1.  Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2.

Authors:  Y C Choi; G T Park; T S Kim; I N Sunwoo; P M Steinert; S Y Kim
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

2.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

3.  Myeloid dendritic cells in inclusion-body myositis and polymyositis.

Authors:  Steven A Greenberg; Geraldine S Pinkus; Anthony A Amato; Jack L Pinkus
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

4.  Myxovirus-like structures and accompanying nuclear changes in chronic polymyositis.

Authors:  S M Chou
Journal:  Arch Pathol       Date:  1968-12

5.  Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model.

Authors:  Michael C Sugarman; Masashi Kitazawa; Michael Baker; Vincent J Caiozzo; Henry W Querfurth; Frank M LaFerla
Journal:  Neurobiol Aging       Date:  2005-06-13       Impact factor: 4.673

6.  Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis.

Authors:  J Nalbantoglu; G Karpati; S Carpenter
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

Review 7.  Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis.

Authors:  Valerie Askanas; W King Engel
Journal:  Curr Opin Rheumatol       Date:  2007-11       Impact factor: 5.006

8.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.

Authors:  Nizar Chahin; Andrew G Engel
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

9.  Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases.

Authors:  M Needham; I James; A Corbett; T Day; F Christiansen; B Phillips; F L Mastaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02-07       Impact factor: 10.154

10.  The ER-bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis.

Authors:  Agnès Delaunay; Kenneth D Bromberg; Yukiko Hayashi; Massimiliano Mirabella; Denise Burch; Brian Kirkwood; Carlo Serra; May C Malicdan; Andrew P Mizisin; Roberta Morosetti; Aldobrando Broccolini; Ling T Guo; Stephen N Jones; Sergio A Lira; Pier Lorenzo Puri; G Diane Shelton; Ze'ev Ronai
Journal:  PLoS One       Date:  2008-02-13       Impact factor: 3.240
View more
  8 in total

Review 1.  Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers.

Authors:  Conrad C Weihl; Alan Pestronk
Journal:  Curr Opin Neurol       Date:  2010-10       Impact factor: 5.710

2.  Formation of gelsolin amyloid fibrils in the rough endoplasmic reticulum of skeletal muscle in the gelsolin mouse model of inclusion body myositis: comparative analysis to human sporadic inclusion body myositis.

Authors:  Sergei I Bannykh; William E Balch; Jeffery W Kelly; Lesley J Page; G Diane Shelton
Journal:  Ultrastruct Pathol       Date:  2013-10       Impact factor: 1.094

3.  A Caenorhabditis elegans model system for amylopathy study.

Authors:  Zhibing Duan; Federico Sesti
Journal:  J Vis Exp       Date:  2013-05-17       Impact factor: 1.355

Review 4.  Clinical applications of intravenous immunoglobulins in neurology.

Authors:  R A C Hughes; M C Dalakas; D R Cornblath; N Latov; M E Weksler; N Relkin
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

5.  Expression of human amyloid precursor protein in the skeletal muscles of Drosophila results in age- and activity-dependent muscle weakness.

Authors:  Chul Kim; Sapeckshita Srivastava; Marian Rice; Tanja A Godenschwege; Brooke Bentley; Saranya Ravi; Shuang Shao; Craig T Woodard; Lawrence M Schwartz
Journal:  BMC Physiol       Date:  2011-04-25

Review 6.  Theories of the pathogenesis of inclusion body myositis.

Authors:  Steven A Greenberg
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.686

Review 7.  Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.

Authors:  Olivier Benveniste; Werner Stenzel; David Hilton-Jones; Marco Sandri; Olivier Boyer; Baziel G M van Engelen
Journal:  Acta Neuropathol       Date:  2015-01-13       Impact factor: 17.088

8.  Vacuolar myopathy in a dog resembling human sporadic inclusion body myositis.

Authors:  Jason King; Richard A LeCouteur; Monica Aleman; D Colette Williams; Peter F Moore; Ling T Guo; Andrew P Mizisin; G Diane Shelton
Journal:  Acta Neuropathol       Date:  2009-08-29       Impact factor: 17.088
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.